Workman P - Search Results

1

Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.

de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A. de Bono JS, et al. Among authors: workman p. Clin Cancer Res. 2008 Oct 15;14(20):6663-73. doi: 10.1158/1078-0432.CCR-08-0376. Clin Cancer Res. 2008. PMID: 18927309 Clinical Trial.

2

Laboratory and phase I studies of new cancer drugs.

Workman P, Kaye SB, Schwartsmann G. Workman P, et al. Curr Opin Oncol. 1992 Dec;4(6):1065-72. doi: 10.1097/00001622-199212000-00011. Curr Opin Oncol. 1992. PMID: 1360819 Review.

3

Pharmacokinetics and early clinical studies of selected new drugs.

Kaye SB, Workman P, Graham MA, Cassidy J, Jodrell D. Kaye SB, et al. Among authors: workman p. Cancer Surv. 1993;17:371-96. Cancer Surv. 1993. PMID: 8137348 Review.

4

Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.

Senan S, Rampling R, Graham MA, Wilson P, Robin H Jr, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, Kaye SB. Senan S, et al. Among authors: workman p. Clin Cancer Res. 1997 Jan;3(1):31-8. Clin Cancer Res. 1997. PMID: 9815534 Clinical Trial.

5

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. Kelland LR, et al. Among authors: workman p. J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9. doi: 10.1093/jnci/91.22.1940. J Natl Cancer Inst. 1999. PMID: 10564678

6

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: workman p. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

7

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR. Kelland LR, et al. Among authors: workman p. Clin Cancer Res. 2001 Nov;7(11):3544-50. Clin Cancer Res. 2001. PMID: 11705875

8

Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.

Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR. Smith V, et al. Among authors: workman p. Clin Cancer Res. 2002 Jun;8(6):2002-9. Clin Cancer Res. 2002. PMID: 12060646

9

Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.

Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Seddon BM, et al. Among authors: workman p. Clin Cancer Res. 2002 Jul;8(7):2323-35. Clin Cancer Res. 2002. PMID: 12114437

10

Assays for HSP90 and inhibitors.

Aherne W, Maloney A, Prodromou C, Rowlands MG, Hardcastle A, Boxall K, Clarke P, Walton MI, Pearl L, Workman P. Aherne W, et al. Among authors: workman p. Methods Mol Med. 2003;85:149-61. doi: 10.1385/1-59259-380-1:149. Methods Mol Med. 2003. PMID: 12710206 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

605 results

Search Page

Filters